Metrics as of 10/13/2026, 06:51 PM (Berlin time), refresh in progress.
Vir Biotechnology Stock
Vir Biotechnology, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Marianne De Backer
- Employees
- 367
- Market cap
- $1.8 B
- IPO
- 11/10/2019
- Web
- www.vir.bio
Vir Biotechnology, Inc. is a healthcare company based in the United States that focuses on devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Founded in 2016, the company is headquartered in San Francisco and employs 367 people. Its pipeline includes several key…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Vir Biotechnology stock: price history
1D
-1.9%
1W
-9.7%
1M
-3.4%
6M
-0.5%
YTD
+72.6%
1Y
+81.9%
2Y
+35.7%
5Y
-73.4%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~5% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Vir Biotechnology
Analyst assessment of Vir Biotechnology
PRICE TARGET LOW
US$22.00
CONSENSUS
US$23.50
MEDIAN
US$23.50
PRICE TARGET HIGH
US$25.00
0
STRONG BUY
10
BUY
2
HOLD
0
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 07/10/2026
Vir Biotechnology stock metrics
P/E
-5.64
P/B
1.78
EV/EBITDA
-5.88
RETURN ON EQUITY
8.2%
NET MARGIN
33.5%
DEBT/EQUITY
0.09
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
76.3%
FLOAT SHARES
128,760,723
AVG. DAILY VOLUME (30D)
2,175,602
Insider transactions (SEC)
MORE ROBERT J
MORE ROBERT J
Coughlin Timothy
Coughlin Timothy
Sabatini Brent
Institutional holders
Comparable stocks
Frequently asked questions about Vir Biotechnology stock
What does Vir Biotechnology do?
Vir Biotechnology, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Marianne De Backer, the company employs around 367 people.
The IPO was on 11/10/2019; the stock trades on NASDAQ under the ticker VIR.
What do analysts say about Vir Biotechnology stock?
12 analysts rate the stock, the consensus is Buy (as of 07/10/2026).
The average price target is US$23.50, ranging from US$22.00 to US$25.00, with a median of US$23.50.
This is an external assessment, not a statement by Market Jury.
When does Vir Biotechnology report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly -5% stronger than usual.
Does Vir Biotechnology pay a dividend?
No, Vir Biotechnology currently does not pay a dividend.
Which stocks are comparable to Vir Biotechnology?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Vir Biotechnology stock analyzed?
Clicking "Analyze stock" lets five strategies assess Vir Biotechnology against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.